Zegocractin

N/A

Report date: 2025/05/28 11:25:46
NME

Base Information

Drug NameZegocractin
Drug Alias NameAuxoraCM-4620CM4620-IECM-128CM_128
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcium release-activated calcium channel protein 1 blockersImmunosuppressantsStromal interaction molecule 1 inhibitors
TargetsCalcium release-activated calcium channel protein 1Stromal interaction molecule 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Systemic Inflammatory Response SyndromeAcute Kidney Injury +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCalcimedica Inc
China Registration ClassN/A

Develop Information

Active CompaniesCalcimedica Inc
Inactive CompaniesUniversity Of Liverpool
Active IndicationsCoronavirus Disease 2019 (COVID-19)Systemic Inflammatory Response SyndromeAcute Kidney Injury +[4] 
Inactive IndicationsPneumonia

Other Information

ATC CodeN/A
Related LinksN/A